Vericel Corp (VCEL)
45.45
-0.66
(-1.43%)
USD |
NASDAQ |
Apr 25, 16:00
45.44
-0.02
(-0.03%)
Pre-Market: 20:00
Vericel Price to Book Value: 9.714 for April 25, 2024
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| April 25, 2024 | 9.714 |
| April 24, 2024 | 9.855 |
| April 23, 2024 | 9.921 |
| April 22, 2024 | 9.699 |
| April 19, 2024 | 9.348 |
| April 18, 2024 | 9.374 |
| April 17, 2024 | 9.887 |
| April 16, 2024 | 10.16 |
| April 15, 2024 | 10.41 |
| April 12, 2024 | 10.24 |
| April 11, 2024 | 10.41 |
| April 10, 2024 | 10.51 |
| April 09, 2024 | 10.76 |
| April 08, 2024 | 10.74 |
| April 05, 2024 | 10.91 |
| April 04, 2024 | 10.78 |
| April 03, 2024 | 10.97 |
| April 02, 2024 | 10.96 |
| April 01, 2024 | 11.31 |
| March 28, 2024 | 11.12 |
| March 27, 2024 | 11.18 |
| March 26, 2024 | 10.59 |
| March 25, 2024 | 10.25 |
| March 22, 2024 | 10.02 |
| March 21, 2024 | 9.978 |
| Date | Value |
|---|---|
| March 20, 2024 | 9.778 |
| March 19, 2024 | 9.752 |
| March 18, 2024 | 9.444 |
| March 15, 2024 | 9.459 |
| March 14, 2024 | 9.448 |
| March 13, 2024 | 9.513 |
| March 12, 2024 | 9.489 |
| March 11, 2024 | 9.530 |
| March 08, 2024 | 9.660 |
| March 07, 2024 | 9.579 |
| March 06, 2024 | 9.656 |
| March 05, 2024 | 9.502 |
| March 04, 2024 | 9.568 |
| March 01, 2024 | 9.555 |
| February 29, 2024 | 9.763 |
| February 28, 2024 | 10.22 |
| February 27, 2024 | 10.26 |
| February 26, 2024 | 10.28 |
| February 23, 2024 | 10.11 |
| February 22, 2024 | 10.32 |
| February 21, 2024 | 10.29 |
| February 20, 2024 | 10.58 |
| February 16, 2024 | 10.52 |
| February 15, 2024 | 10.55 |
| February 14, 2024 | 10.16 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
2.933
Minimum
Mar 18 2020
22.42
Maximum
Jun 28 2021
9.424
Average
8.138
Median
Dec 19 2023
Price to Book Value Benchmarks
| Arbutus Biopharma Corp | 4.623 |
| Chimerix Inc | 0.4118 |
| Karyopharm Therapeutics Inc | -- |
| Axsome Therapeutics Inc | 17.74 |
| Y-mAbs Therapeutics Inc | 6.433 |
Price to Book Value Related Metrics
| PS Ratio | 10.95 |
| Price to Free Cash Flow | 277.37 |
| Price | 45.45 |
| Earnings Yield | -0.18% |
| Market Cap | 2.195B |